Halozyme Therapeutics shares reach new 52-week high

Halozyme Therapeutics (NASDAQ: HALO) reached a new 52-week high during recent trading, with the share price hitting as high as $109.10. The company currently maintains a market capitalization of $12.33 billion.

Financial analysts have provided various ratings for the stock. Recent actions include Leerink Partners raising its rating from ‘market perform’ to ‘outperform’ with a target price of $110.00, and Wall Street Zen upgrading the stock to a ‘strong-buy’. Other institutions, such as UBS Group and Benchmark, have maintained ‘buy’ ratings, while Morgan Stanley adjusted its price objective to $93.00 with an ‘overweight’ rating.

Overall, the consensus among nine analysts is a ‘Buy’ rating, with three issuing ‘Hold’ ratings and one ‘Sell’ rating. The average target price stands at $91.20.